Pretraga

Rezultati

Active surveillance of cervical intraepithelial neoplasia grade 2: 2025 British Society of Colposcopy and Cervical Pathology and European Society of Gynaecologic Oncology consensus statement [2025]

Kyrgiou, Maria; Bowden, Sarah J; Ellis, Laura Burney; Hammer, Anne; Lyons, Deirdre; Freeman, Wang Theresa; Kechagias, Konstantinos S; Kalliala, Ilkka; Preti, Mario; Kesic, Vesna I;

Zapardiel, Ignacio; Cruickshank, Margaret; Gultekin, Murat; Martin, Hirsch Pierre;

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial [2014]

Stupp, Roger; ...; Grujicic, Danica M; ...; (broj, koautora 37)

2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19 [2022]

Farge, Dominique; ...; Antić, Darko A. ; ...; International Initiative on Thrombosis and Cancer (ITAC) advisory panel; (broj koautora 19)

Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data [2013]

Mauguen, Audrey; Pignon, Jean-Pierre; Burdett, Sarah; Domerg, Caroline; Fisher, David; Paulus, Rebecca; Mandrekar, Samithra J; Belani, Chandra P; Shepherd, Frances A; Eisen, Tim;

Pang, Herbert; Collette, Laurence; Sause, William T; Dahlberg, Suzanne E; Crawford, Jeffrey; O'Brien, Mary; Schild, Steven E; Parmar, Mahesh; Tierney, Jayne F; Pechoux, Cécile Le; Michiels, Stefan;

Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis [2021]

Petit, Claire; ...; Jeremic, Branislav; ...; (broj, koautora 35)

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial [2015]

Thatcher, Nick; Hirsch, Fred R; Luft, Alexander V; Szczesna, Aleksandra; Ciuleanu, Tudor E; Dediu, Mircea; Ramlau, Rodryg; Galiulin, Rinat K; Bálint, Beatrix; Losonczy, György;

Kazarnowicz, Andrzej; Park, Keunchil; Schumann, Christian; Reck, Martin; Depenbrock, Henrik; Nanda, Shivani; Kruljac-Letunic, Anamarija; Kurek, Raffael; Paz-Ares, Luis; Socinski, Mark A;

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Group [2017]

M. Miguel; F. Holmes; B. Ejlertsen; S. Delaloge; B. Moy; H. Iwata; G. von Minckwitz; S. Chia; J. Mansi; C. Barrios;

Tomašević, Zorica I. ; M. Gnant...et al.; ExteNET Study Group;

Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial [2019]

Tan, Antoinette R; ...; Popovic, Lazar S ; ...; Milenkovic, Dusan M; ...; (broj, koautora 17)

Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study [2014]

Davies, Andrew; Merli, Francesco; Mihaljević, Biljana ; Siritanaratkul, Noppadol; Solal-Céligny, Phillippe; Barrett, Martin; Berge, Claude; Bittner, Beate; Boehnke, Axel; McIntyre, Christine;

MacDonald, David;

Melanoma of the small intestine [2009]

Lens, Marko; Bataille, Veronique; Krivokapic, Zoran V